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Data from genetic, epidemiologic, and immunologic stud-
ies suggest an immune-mediated pathogenesis of narcolepsy 
type 1. The association with the HLA class II allele DQB1*06, 
which is much stronger than in many other known autoimmune 
diseases, and the description of triggering factors strongly sup-
port the concept of an autoimmune-mediated loss of hypocre-
tin-producing cells.1,2 Although results were conflicting, case 
series of few or single patients receiving different immune 
therapies, such as intravenous immunoglobulins, plasmapher-
esis, corticosteroids or the lymphocyte depleting monoclonal 
antibody alemtuzumab, challenged the question whether nar-
colepsy patients could benefit from such interventions.3–9
In the current issue of the Journal of Clinical Sleep Medi-
cine, Lecendreux et al. report on the—thus far—largest longi-
tudinal follow-up study of pediatric patients with narcolepsy 
treated with intravenous immunoglobulins (IVIg) as an off-la-
bel therapy in a large national reference center for narcolepsy. 
Overall, the results do not show a significant advantage of IVIg 
on narcolepsy symptoms in this cohort but the authors suggest 
a potential effect of the therapy in a subset of patients with 
more severe baseline symptoms.10 Clearly the data have to be 
interpreted with caution and do not allow a definite conclusion 
on the efficacy of this immunotherapy in narcolepsy. Because 
the study is retrospective case series, lacking defined inclusion 
and exclusion criteria, there is an inherent bias in the selection 
of patients that is also reflected in the baseline characteristics 
of the study population. The authors have made all possible 
efforts to account for that bias in their statistical analysis, but 
were not able to fully delineate whether there was an indepen-
dent effect of the IVIg treatment or whether it merely reflected 
a difference in the natural course of the disease. Nevertheless, 
there is a possibility that a subset of narcolepsy patients im-
proved because of the treatment.
Such efforts are important to enhance our understanding of 
the disease but further steps are needed to advance the field 
toward new therapeutic approaches targeting specific immune 
processes in narcolepsy patients. Immunotherapeutic interven-
tions provide an opportunity to approach essential questions on 
the immunopathogenesis of the disease. Therefore, controlled 
clinical trials should ideally be accompanied by thorough 
mechanistic studies aiming to dissect the main pathogenic 
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components and identify biomarkers for future stratification of 
patients. Evidence for an autoantibody-mediated pathogenesis 
has been provided in different cohorts and distinct mechanisms 
have been described among patients with narcolepsy related to 
vaccination.11–14 The role of the cellular immune response in 
the disease remains less clear and better understanding will 
guide targeted therapeutic strategies.15,16
An additional important aspect is to improve stratification of 
patients to increase the validity of future randomized clinical 
trials. Along with certain clinical aspects such as the associa-
tion of narcolepsy with vaccination, research should focus on 
the development of appropriate biomarkers to identify patients 
who are more likely to respond to certain immune therapies.
Studies like the one by Lecendreux et al.10 are essential to 
raise awareness about immune interventions in narcolepsy and 
help reduce the time gap between disease onset and treatment 
initiation. Although the study could not support the concept for 
early treatment, in some of the prior studies treatment effects 
were more promising if started early after disease onset.
Lecendreux et al. have made the first step toward therapeu-
tic intervention studies in larger cohorts of pediatric patients 
with narcolepsy with a longer follow-up period. Finally, the 
time has come for randomized, controlled immunotherapy tri-
als with the prospects for a new treatment era in narcolepsy.
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